Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 10 December. Sara Barrington.

Executive Summary

Kantaro Biosciences, a joint venture between Mount Sinai Health System and Renalytix AI, expects its SARS-COV-2 IgG antibody test kit will allow researchers and public health officials to track the effectiveness of the COVID-19 vaccination programs that will likely begin soon. See what Kantaro’s chief commercial officer Sara Barrington said about it here.

“Accessibility is going to be very important, especially as we're going into sort of a messy part of the transition in the pandemic.” – Sara Barrington, chief commercial officer, Kantaro

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts